S&P 5007,675.92▼0.4% Nasdaq26,749.30▼0.7% Dow51,245.74▼0.5% Russell 2K2,826.40▼0.4% 10-Yr5.12%+1bp VIX15.69+0.51 WTI$95.27▲3.4% Gold$4,292.50▼0.6% EUR/USD1.138▼0.6% BTC$84,310▼0.1% Nikkei65,514▲0.8%
At close · Thu, Sep 24, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›Samsung Biologics makes $1.8 billion all-cash bid for…

Samsung Biologics makes $1.8 billion all-cash bid for PolyPeptide

The offer values PolyPeptide at 1.46 billion Swiss francs, or about $1.8 billion, and is structured as an all-cash transaction.

Reported · Written up by our desk · M&A & Deals

Samsung Biologics has made an all-cash bid for Switzerland-based PolyPeptide Group, according to CNBC Markets. The proposed deal is for 1.46 billion Swiss francs, which CNBC World reported as equivalent to about $1.8 billion.

Samsung Biologics said the offer is 100% cash, reflecting a fully cash transaction structure for the acquisition.

← Newer storyTrump tells Carney Canada must do more on Ontario wildfire smoke

More like this

US MarketsKFC opens a new Texas restaurant concept to test customer service
US MarketsSony, A24 and The New York Times Company register interest in Letterboxd
US MarketsNew York sues Polymarket U.S. over alleged gambling law violations
US MarketsMay Mobility to go public via SPAC merger valued near $1.4 billion
US MarketsSK Hynix weighs US memory chip plans with Intel’s Ohio site

Sources

CNBC MarketsSamsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group
CNBC WorldSamsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.